Learning Objectives. Non-alcoholic Fatty Liver Disease (NAFLD) (Fatty Liver) What is Fatty Liver (Non-Alcoholic Fatty Liver)? Fatty Liver (NAFLD)

Similar documents
Non-alcoholic fatty liver disease: Prognosis and Treatment

NASH: It is not JUST a Fatty Liver. Karen F. Murray, M.D. Director of Hepatobiliary Program Children s Hospital and Regional Medical Center

NP/PA Clinical Hepatology Fellowship Summary of Year-Long Curriculum

BACKGROUND MEDIA INFORMATION Fast facts about liver disease

Non-Alcoholic Fatty Liver Disease

Primary Care Guidance Program: Non-Alcohol related Fatty Liver Disease (NAFLD) Guidance on Management in Primary Care

Differential Diagnosis of NAFLD- A Short Summary:

MANAGEMENT OF LIVER CIRRHOSIS

Liver Function Essay

THE ENDOCANNABINOID SYSTEM AS A THERAPEUTIC TARGET FOR LIVER DISEASES. Key Points

Role of Body Weight Reduction in Obesity-Associated Co-Morbidities

Liver Function Tests - The Downside

Prof. of Tropical Medicine Faculty of Medicine Alexandria University

Non Alcoholic Steato-Hepatitis (NASH)

Alcohol and the Liver

DR. Trinh Thi Kim Hue

Approach to Abnormal Liver Tests

Patterns of abnormal LFTs and their differential diagnosis

The Epidemiology of Hepatitis A, B, and C

Abnormal Liver Function. Dr William Alazawi MA(Cantab) PhD MRCP Senior Lecturer and Consultant in Hepatology Queen Mary, University of London

Amylase and Lipase Tests

Do You Know the Health Risks of Being Overweight?

LIVER CANCER AND TUMOURS

Subproject 4: Specification and Documentation of Metabolic and Neoplastic Diseases

The most serious symptoms of this stage are:

Alanine aminotransferase (serum, plasma)

Surveillance for Hepatocellular Carcinoma

What to do with abnormal LFTs? Andrew M Smith Hepatobiliary Surgeon

Liver Diseases. An Essential Guide for Nurses and Health Care Professionals

BURDEN OF LIVER DISEASE IN BRAZIL

Indications in Hepatology and Liver Diseases

IS VITAMIN E SAFE TO USE?

Catholic Medical Center & Androscoggin Valley Hospital. Surgical Weight Loss Options For a Healthier Tomorrow

HEALTH NEWS PROSTATE CANCER THE PROSTATE

Body Composition & Longevity. Ohan Karatoprak, MD, AAFP Clinical Assistant Professor, UMDNJ

Hepatology Guidelines for Primary Care November 2011

ARTICLE #1 PLEASE RETURN AT THE END OF THE HOUR

Evaluation of Liver Function tests in Primary Care. Abid Suddle Institute of Liver Studies, KCH

Is Insulin Effecting Your Weight Loss and Your Health?

NUTRITION IN LIVER DISEASES

Non-alcoholic Fatty Liver Disease (NAFLD): Does Anything Help?

Bile Duct Diseases and Problems

understanding CIRRHOSIS of the liver A patient s guide from your doctor and

Statistics of Type 2 Diabetes

Nutrition. Type 2 Diabetes: A Growing Challenge in the Healthcare Setting NAME OF STUDENT

ELEMENTS FOR A PUBLIC SUMMARY. Overview of disease epidemiology. Summary of treatment benefits

NORD Guides for Physicians #1. Physician s Guide to. Tyrosinemia. Type 1

Liver, Gallbladder, Exocrine Pancreas KNH 406

What to Do with the Patient With Abnormal Liver Enzymes? Nizar N. Zein, M.D. The Cleveland Clinic

Boehringer Ingelheim- sponsored Satellite Symposium. HCV Beyond the Liver

Metabolic Syndrome Overview: Easy Living, Bitter Harvest. Sabrina Gill MD MPH FRCPC Caroline Stigant MD FRCPC BC Nephrology Days, October 2007

Opportunities for advancing biomarkers for patient stratification and early diagnosis in liver disease

Cirrhosis and HCV. Jonathan Israel M.D.

NAFLD/NASH: Criteri diagnostici e prognostici

Surgical Weight Loss Center Patient Intake Form

SHAHID AZIZ DO, FACOI.

Hemochromatosis. National Digestive Diseases Information Clearinghouse

GT-020 Phase 1 Clinical Trial: Results of Second Cohort

Adams Memorial Hospital Decatur, Indiana EXPLANATION OF LABORATORY TESTS

Liver Transplantation for Hepatocellular Carcinoma. John P. Roberts, MD Chief, Division of Transplant Service University of California, San Francisco

Alcohol: The good, the bad and

2.1 AST can be measured in heparin plasma or serum. 3 Summary of clinical applications and limitations of measurements

Insulin sensitisers in the treatment of non-alcoholic fatty liver disease: a systematic review

Evaluation of abnormal LFT in the asymptomatic patient. Son Do, M.D. Advanced Gastroenterology Vancouver, WA

Hepatitis C Treatment Expansion Initiative Multi-Site Conference Call. March 16, 2011

Diabetes and Obesity in Children. Janie Berquist, RN, BSN, MPH, CDE Children s Mercy Hospitals and Clinics Kansas City, MO

NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) IN MEN WITH TYPE 2 DIABETES

Hepatitis C Glossary of Terms

ICD-9-CM/ICD-10-CM Codes for MNT

Liver means Life. Why this manifesto? We are eager to ensure. that we can contribute. to society as much. as possible, and we. are equally keen to

Two Cases of Non-Alcoholic Steato-Hepatitis Developing from Simple Fatty Liver

BREAST CANCER AWARENESS FOR WOMEN AND MEN by Samar Ali A. Kader. Two years ago, I was working as a bedside nurse. One of my colleagues felt

Service Definition with all Clinical Terms Service: Laprascopic Cholecystectomy Clinic (No Gallstones in bile duct)

Intracellular fat deposition

LIVER FUNCTION TESTS AND STATINS

New IDSA/AASLD Guidelines for Hepatitis C

Alcoholic hepatitis describes liver inflammation caused by drinking alcohol.

Update on Hepatitis C. Sally Williams MD

Cardiovascular Disease Risk Factors

CME Test for AMDA Clinical Practice Guideline. Diabetes Mellitus

BMC Med 7/19/2007; Simvastatin linked to reduced incidence of dementia, Parkinson s disease.

Fatty liver and NASH. Fighting liver disease

PowerPoint Lecture Outlines prepared by Dr. Lana Zinger, QCC CUNY. 12a. FOCUS ON Your Risk for Diabetes. Copyright 2011 Pearson Education, Inc.

Recommendations for the Identification of Chronic Hepatitis C virus infection Among Persons Born During

Treating Patients with PRE-DIABETES David Doriguzzi, PA-C First Valley Medical Group. Learning Objectives. Background. CAPA 2015 Annual Conference

Transmission of HCV in the United States (CDC estimate)

Using Family History to Improve Your Health Web Quest Abstract

GloP1r - A New Frontier in Exercise and Nutrition

TABLE OF CONTENTS. The Cost of Diabesity Employer Solutions... 4 Provide a Worksite Weight Loss Program Tailored for Diabetes...

Geir Folvik, MD Division of Gastroenterology Department of Medicine, Haukeland University Hospital Bergen, Norway

Cardiovascular Disease Risk Factors Part XII Insulin Resistance By James L. Holly, MD Your Life Your Health The Examiner September 15, 2005

Karen Kovach M.S, R.D Chief Scientific Officer Weight Watchers International Inc.

SARCOIDOSIS. Signs and symptoms associated with specific organ involvement can include the following:

Non-Alcoholic Fatty Liver Disease: A Patient s Guide

Alcoholic Liver Disease and Its Relationship with Metabolic Syndrome

Section 2. Overview of Obesity, Weight Loss, and Bariatric Surgery

National Digestive Diseases Information Clearinghouse

Evaluation and Prognosis of Patients with Cirrhosis

Male New Patient Package

4/4/2013. Mike Rizo, Pharm D, MBA, ABAAHP THE PHARMACIST OF THE FUTURE? METABOLIC SYNDROME AN INTEGRATIVE APPROACH

Transcription:

Learning Objectives Non-alcoholic Fatty Liver Disease (NAFLD) (Fatty Liver) Smruti R. Mohanty, MD, MS Assistant Professor of Medicine Center for Liver Diseases Section of Gastroenterology University of Chicago September 29, 2006 Define Fatty liver History of Fatty Liver Rate of Fatty liver Demographic Features and racial variations in fatty liver Risk Factors for fatty liver Relationship between metabolic syndrome and Fatty Liver Development of Fatty Liver Clinical Presentation & Diagnosis of Fatty Liver Role of Liver Biopsy in Fatty Liver Natural History of Fatty Liver Treatment of Fatty Liver What is Fatty Liver (Non-Alcoholic Fatty Liver)? Simple term called Fatty Liver This is a spectrum of disorder characterized by accumulation fat within the liver cells, with / without inflammation of liver or liver cell injury or damage. Patients lack the significant history of alcohol drinking. Diehl et al., Gastroenterology 1988; 95: 1056-1062 Teli MR et al. Hepatology 1995; 22: 1714-1719 Fatty Liver (NAFLD) Fatty Liver (NAFLD) can be progressive Fat accumulation in liver (Steatosis) Fat + Inflammation and liver cell injury or damage ------ Non-alcoholic steatohepatitis ( NASH) Non-alcoholic steatohepatitis + Fibrosis (scar tissue in the liver) Cirrhosis (multiple nodules formation from scar tissue) Liver Cancer (Cancer from Liver Cells) Diehl et al., Gastroenterology 1988; 95: 1056-1062 Teli MR et al. Hepatology 1995; 22: 1714-1719 1

What is the History of Fatty Liver ( NAFLD / NASH)? Fatty Liver has been known for two decades Non-alcoholic steatohepatitis (fat + inflammation + scar tissue) a subset or spectrum of Fatty liver 1980-First reported by Ludwig et al. at Mayo In liver biopsy, features of alcoholic Hepatitis suggestive of fatty Liver (identical to alcohol related liver damage due to drinking) Patients lack a significant history of alcohol drinking Ludwig et al. Mayo Clinic Proceedings1980;55:434-438 What is the Rate/risk of Fatty liver in general population? True rate of fatty liver in general population is lacking. It may be more common disease in general population. Most diagnosis are made by imaging or liver tests Inability to distinguish between simple fatty liver vs. fat with inflammation /or damage (NASH) or Cirrhosis Studies with liver biopsies looked at specific groups such as obesity or diabetes Selection bias or referral bias Falck-Ytter Y. Semin Liver Dis 2001;21: 17-26 What is the Rate/risk of Fatty liver in general population? (Cont.) population based studies (radiology survey, postmortem studies) 16% - 23 % of general population NASH (fat with damage to liver) in 2% - 6 % cases Fatty liver in Children 2.6 % of pediatric population 22.5% - 52.5 % of children with obesity Some children have cirrhosis Araujo LMB et al. Diabet & Metab 1998; 24: 458-462 Ballentani S et al. Ann Intern Med 2000; 132:112-117 Clark JM et al. Gastro 2002; 122:1649-1657 Ruhl CE et al. Gastro 2003; 124:71-79 Demographic Features Increased rate of obesity over last three decades Entire spectrum of fatty liver in all age groups Highest rates in 4 th or 5 th decades (40 or 50 years) of life Fatty Liver affects both sexes equally True rate among various racial and ethnic groups is not fully known Mexican Americans > Caucasians > African Americans Lower prevalence of NAFLD among African Americans, may be related to referral patterns, genetic differences and lack of disease recognition. 2

Demographic Features (Cont.) Familial Clustering (Several members of family) Person s genetic factors may play a major role, but data is not available Studies on Multiple Family members with fatty liver No clear inheritance patterns Diabetes and Obesity (risk factors for fatty liver) showed familial clustering Rare familial disorders or diseases Abetalipoproteinemia and lipodystropies lead to fatty liver and cirrhosis Different pattern of Genes may play role in the development of of fatty liver in these disorders Racial and Ethnic Variations in fatty liver Ruhl et al. Gastroenterology 2003;124:71-79 What are the major risk factors? Other Risk Factors for fatty liver Metabolic syndrome (Diabetes, Over weight, High Blood pressure, high cholesterol) Diabetes Obesity Alcohol TPN (nutrition through vein) Wilson diseases Jejunoileal bypass Starvation Lipodystrophy Abetalipoproteinemia Weber-Christian Syndrome Industrial Toxins Hypothyroidism (low thyroid function Medications Corticosteroids Amiodarone Tamoxiphen Diltiazem Nifedipine Methotrexate HAART (HIV drugs) 3

Metabolic Syndrome and Fatty Liver Fatty liver is associated with Metabolic syndrome (Insulin resistance) Obese, diabetes and high triglyceride (fat in the blood) 60%-95% of patients with Fatty Liver are obese In Morbid obese, the rate of fatty liver is > 95% & rate of fatty with damage/scar tissue (NASH) is approximately 25 % 21%-55% of patients with fatty liver have Diabetes Diabetes is associated with advanced scar tissue or cirrhosis 21%-55% of patients with fatty liver have high triglyceride (fat in the blood) Dixon et al. Gastro 2001, Angulo et al. Hepatology 1999, Powel et al. Hepatology,1990, Bacon et a. Gastro 1994, Mokdad et al. JAMA 2001 Relationship between insulin resistance and Fatty Liver DM and Obesity leads insulin Resistance (IR) Insulin Resistance Fat in Liver Questions Clinical Presentation of NAFLD How do we make diagnosis of NAFLD / NASH? Which patients need Liver Biopsy? How do we manage these cases? Is NAFLD / NASH lead to cirrhosis? Symptoms Asymptomatic Non-specific symptoms Symptoms related to Metabolic syndrome Fatigue is very common Symptoms of Sleep apnea related to obesity Occasionally, RUQ pain Common in children Signs Obesity is most common High blood pressure Hepatomegally (50%) Signs related chronic liver diseases Muscle wasting Pruritus, anorexia and Jaundice (advanced liver dysfunction) Signs of portal hypertension 4

Laboratory Abnormalities Elevated liver tests when checked for nonspecific symptoms 30% - 50 % have Diabetes or Glucose intolerance 20% - 80 % have High cholesterol What is the role of Imaging studies in Fatty Liver? U/S, CT and MRI Fatty infiltration in liver Can not differentiate simple fat vs fat with scar tissue Unable to recognize hepatic scar Morbid obese individuals ultrasound image may be poor and unable to recognize liver fat Is there a role of Liver Biopsy in Fatty liver? Simple fatty liver Liver biopsy is gold standard for the diagnosis It can differentiate simple fat vs fat with inflammation and scar tissue Stages of scar and/ or Cirrhosis 20 % patients with increased liver tests may have alternate diagnosis on liver biopsy Liver biopsy should be individualized 5

Fat with inflammation Hepatitis with scar tissue Advanced fatty liver with cirrhosis How do we make a diagnosis of Fatty Liver? The patient have no significant alcohol intake No more than 1-2 drinks per day Other liver diseases be ruled out HCV, Wilson s disease and drugs etc. Fatty liver may co-exist with other liver diseases The liver biopsy feature compatible with fatty liver 6

What is Natural History of Fatty Liver? Can fatty liver be progressive? What is the prognosis? Does fatty liver disease lead to liver cancer? Can Fatty Liver be progressive? Generally, patients with simple fat in liver have non-progressive fatty liver But one study has shown that simple fat liver may progress to progressive liver disease Fatty liver may progress to cirrhosis and can have liver related death Matteoni CA et al.,gastro 1999, Teli MR et al.,hepatology 1995, Harrison SA et al., Am J Gastro 2003 and Ong JP et al., AM J Gastro 2003 Does Fatty Liver disease lead to liver cancer? Natural History of Fatty Liver (NAFLD) Normal Liver Data also suggest that fatty liver may be an important cause of cirrhosis and liver cancer. Simple Fat Fatty Liver + Scar tissue Fat + Inflammation 20 % Cirrhosis Liver Cancer 7

Treatment of Fatty Liver Currently, there is no proven effective therapy. Focus on modifying associated conditions Metabolic Syndrome Diabetes Obesity High Cholesterol Treatment of Fatty Liver (Cont.) Weight loss Wt. loss > 10 % leads improvement of liver enzymes and improvement of fat Rapid Wt. loss may lead to increased inflammation and scar tissue in liver including liver failure Gradual wt. loss of 10 % of baseline wt is recommended No significant data on liver scar tissue improvement those who lost weight Management of high cholesterol Cholesterol lowering agents may be associated improvement of liver cell injury, inflammation and liver tests Treatment of Fatty Liver (Cont.) Increase insulin sensitivity Metformin Pilot study (14 patients) showed improvement of LFTs Thiazolindinediones Rosiglitazone & Pioglitazone (diabetic drugs) Liver test and liver inflammation/ scar tissue improvement Potential liver toxicity Those drugs are not FDA approved for fatty liver yet. Marchesini et al. Lancet 2001 Neuschwander-Tetri et al., Hepatology 2003 Promrat K et al, Hepatology 2004 Treatment of Fatty Liver (Cont.) Vitamin E Small pilot studies showed improvement of liver tests and liver inflammation / scar tissue in obese children and patients with fatty liver Lavine JE. J Pediatrics, 2000, Hasegawa et al., Aliment Pharmacol Ther 2001 Adelmalek MF et al. Am J Gastro 2001, Gulbahar et al. Gastro 2000 (Abstract) 8

Summary Growing incidence of obesity in general population has made fatty liver disease and its complications the major public health issue. Fatty liver disease is associated with nonspecific symptoms. Asymptomatic presentation does not imply benign course. Fatty Liver can be progressive and may lead to cirrhosis and liver cancer. Summary (Cont.) Currently, there is no proven effective treatment or therapy. Mainstay of treatment is therapy for associated conditions such as metabolic syndrome, control of diabetes, high cholesterol and weight loss. Thank you 9